European journal of pharmacology · 2026
Systemic Modulation of Group II mGluRs Increases Extracellular Lactate in the Rat Prefrontal Cortex.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ikegaki Yujiro, Itoh Hiroko, Senoo Takanori, Sumita Daisuke, Nagasawa Tatsuya, Ikeda Eiji, Takahashi Tsutomu, Uehara Takashi
Аннотация
BACKGROUND: Lactate is increasingly recognized as a dynamic indicator of neuronal activity and brain energy metabolism and is closely linked to glutamatergic neurotransmission via the astrocyte-neuron lactate shuttle. Group II metabotropic glutamate receptors (mGluR2/3) regulate glutamate release and have been implicated in psychiatric disorders; however, their role in cortical lactate metabolism remains unclear.
METHODS: In this study, we examined the effects of pharmacological modulation of mGluR2/3 on extracellular lactate concentration (eLAC) in the medial prefrontal cortex of naïve rats using in vivo microdialysis. Systemic administration of an mGluR2/3 agonist (LY354740), an mGluR2 positive allosteric modulator (LY487379) and selective antagonists were evaluated. To explore the potential involvement of mGluR3 in cortical metabolism, we evaluated the effects of 2-PMPA, a glutamate carboxypeptidase II (GCP-II) inhibitor that increases endogenous levels of N-acetylaspartylglutamate (NAAG), which preferentially activates mGluR3 over mGluR2.
RESULTS: Systemic administration of LY354740 or LY487379 unexpectedly increased eLAC. These effects of LY354740 and LY487379 were prevented by the mGluR2 antagonist Ro 64-5229. In addition, systemic administration of 2-PMPA increased eLAC, and this effect was blocked by LY341495, an mGluR2/3 antagonist.
CONCLUSIONS: These findings indicate that systemic modulation of group II mGluRs may engage indirect network-level mechanisms that influence cortical energy metabolism. These results provide new insight into the relationship between glutamatergic signaling and brain metabolic dynamics.
METHODS: In this study, we examined the effects of pharmacological modulation of mGluR2/3 on extracellular lactate concentration (eLAC) in the medial prefrontal cortex of naïve rats using in vivo microdialysis. Systemic administration of an mGluR2/3 agonist (LY354740), an mGluR2 positive allosteric modulator (LY487379) and selective antagonists were evaluated. To explore the potential involvement of mGluR3 in cortical metabolism, we evaluated the effects of 2-PMPA, a glutamate carboxypeptidase II (GCP-II) inhibitor that increases endogenous levels of N-acetylaspartylglutamate (NAAG), which preferentially activates mGluR3 over mGluR2.
RESULTS: Systemic administration of LY354740 or LY487379 unexpectedly increased eLAC. These effects of LY354740 and LY487379 were prevented by the mGluR2 antagonist Ro 64-5229. In addition, systemic administration of 2-PMPA increased eLAC, and this effect was blocked by LY341495, an mGluR2/3 antagonist.
CONCLUSIONS: These findings indicate that systemic modulation of group II mGluRs may engage indirect network-level mechanisms that influence cortical energy metabolism. These results provide new insight into the relationship between glutamatergic signaling and brain metabolic dynamics.